Gsk Plc ADR (GSK) Stock Price, Quote & News

Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephr...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 44 20 8047 5000

Website: www.gsk.com

Address:

79 New Oxford Street, London, United Kingdom

Financial_Doc Oct. 24 at 2:59 PM

$GSK what's going on here after FDA approval?

1 · Reply

OpenOutcrier Oct. 24 at 12:23 PM

$GSK (-5.0% pre) GSK shares fall as narrow approval of blood cancer drug limits US relaunch https://ooc.bz/l/81736

0 · Reply

Paulzk Oct. 24 at 10:21 AM

$GSK Not the final word on GSK multiple myeloma , another in phase 2 , phase 1 and 2 newly registered. Many drugs in the pipeline. buy the dip https://www.gsk.com/en-gb/innovation/pipeline/

0 · Reply

AlertsAndNews Oct. 24 at 2:36 AM

$GSK FDA Approves Blenrep for Relapsed/Refractory Multiple Myeloma GSK announced the U.S. FDA approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone for adults with relapsed or refractory multiple myeloma after at least two prior therapies. The approval was supported by the phase III DREAMM-7 trial, which showed a 51% reduction in risk of death and tripled median progression-free survival versus a daratumumab-based regimen.

0 · Reply

drewfin87 Oct. 23 at 9:55 PM

$GSK what’s up with the price action at the end of today? That bounce off of news was sold off so fast that I thought it was a glitch…

2 · Reply

SuperGreenToday Oct. 23 at 9:49 PM

$GSK Share Price: $46.70 Contract Selected: Nov 14, 2025 $45 Calls Buy Zone: $1.27 – $1.58 Target Zone: $2.14 – $2.61 Potential Upside: 58% ROI Time to Expiration: 21 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Whytheykeepmutingme Oct. 23 at 9:15 PM

$GSK fda approval is bad news?

0 · Reply

OptionRunners Oct. 23 at 8:01 PM

$GSK Blenrep has been approved by the US FDA for treating relapsed or refractory multiple myeloma. The DREAMM-7 trial showed a 51% reduction in risk of death and tripled median outcomes, with interim first-line efficacy and safety data expected by early 2028.

0 · Reply

CrispDry Oct. 23 at 8:01 PM

$GSK the heck?

0 · Reply

levans80 Oct. 23 at 7:59 PM

$GSK Closed out some call options right before the bell. Nice profit on that spike into close.

0 · Reply

GSK shares fall as narrow approval of blood cancer drug limits US relaunch

Oct 24, 2025, 1:23 AM EDT - 1 day ago

FTSE 100 Index shares to watch: HSBC, Standard Chartered, Haleon, GSK

HLN

$Blenrep approved by US FDA for use in treatment of relapsed/refractory multiple myeloma$

Oct 23, 2025, 8:11 PM EDT - 1 day ago

Blenrep approved by US FDA for use in treatment of relapsed/refractory multiple myeloma

Oct 23, 2025, 4:05 PM EDT - 1 day ago

US FDA approve GSK's blood cancer treatment

Oct 16, 2025, 7:02 PM EDT - 8 days ago

UK's drug-cost watchdog recommends use of GSK unit's HIV prevention drug

Oct 10, 2025, 2:57 PM EDT - 14 days ago

GSK: Compelling Value, No Red Flags Ahead Of Earnings, Blenrep FDA Decision Soon

Oct 9, 2025, 1:22 PM EDT - 15 days ago

GSK's Hidden Growth Engines Beyond HIV And Oncology

Oct 6, 2025, 1:29 PM EDT - 18 days ago

My Top 5 Biotech Stocks Big Pharma Could Buy Next

ABBV ALVO AMGN ARKG AZN BIIB BMY

Oct 6, 2025, 6:02 AM EDT - 19 days ago

Focus: US Health Secretary Kennedy speeds autism drug with GSK help

Oct 1, 2025, 10:00 AM EDT - 23 days ago

New Local Data in GSK and IQVIA's Vaccine Track Supports Smarter Public Health Action at the Community Level

Oct 1, 2025, 7:58 AM EDT - 24 days ago

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields

BMY XRAY

Sep 29, 2025, 10:00 AM EDT - 25 days ago

Emma Walmsley To Step Down As GSK CEO After Nine Years, Luke Miels To Lead Starting January 2026

Sep 29, 2025, 4:46 AM EDT - 26 days ago

GSK turns to insider to be next CEO — and the stock rallies

Sep 29, 2025, 4:20 AM EDT - 26 days ago

Who is GSK's next CEO Luke Miels?

Sep 29, 2025, 3:59 AM EDT - 26 days ago

GSK names Luke Miels as next CEO after Emma Walmsley steps down; shares jump

Sep 29, 2025, 2:07 AM EDT - 26 days ago

GSK names Luke Miels as CEO designate

Sep 24, 2025, 9:43 AM EDT - 4 weeks ago

GSK plc (GSK) plc Presents at Bank of America Global Healthcare Conference 2025 Transcript

Sep 24, 2025, 7:45 AM EDT - 4 weeks ago

Pi Health to Collaborate with GSK to Enhance Clinical Research Services

Sep 22, 2025, 6:20 PM EDT - 4 weeks ago

GSK to submit label update for Leucovorin at FDA's request, does not intend to market it for autism

Sep 22, 2025, 4:55 PM EDT - 4 weeks ago

FDA approves drug that Trump due to suggest as autism treatment

Sep 17, 2025, 2:29 AM EDT - 5 weeks ago

UK's GSK announces $30 billion U.S. pharma investment amid Trump state visit

Sep 16, 2025, 8:00 PM EDT - 5 weeks ago

GSK and Eli Lilly are the latest multinational drugmakers to unveil plans to build more U.S. manufacturing plants and other operations, moves aimed partly at mitigating the threat of tariffs

LLY

Sep 16, 2025, 7:08 PM EDT - 5 weeks ago

GSK plans $30 billion US investment as pharma tariff threat looms

Sep 16, 2025, 7:01 PM EDT - 5 weeks ago

GSK Says It Will Spend $30B on U.S. Manufacturing and R&D

Sep 15, 2025, 7:44 AM EDT - 5 weeks ago

Dividend Income Summary: Lanny's July 2025 Summary

BNL BNS CM CSCO IRM ITW LEG

Sep 10, 2025, 1:03 PM EDT - 6 weeks ago

US tariffs, pricing risks to be manageable for Big Pharma, Morningstar says

ABBV AZN NVO NVS SNY AMGN LLY

Sep 3, 2025, 1:28 PM EDT - 7 weeks ago

Why Is GSK Partner Wave Life Sciences Stock Trading Lower On Wednesday?

WVE

Aug 21, 2025, 8:22 AM EDT - 2 months ago

Dynavax's shingles vaccine shows similar immune response to GSK's shot in study

DVAX

Aug 11, 2025, 2:15 AM EDT - 2 months ago

GSK's antibiotic drug gepotidacin gets priority review by FDA

Aug 8, 2025, 3:31 AM EDT - 2 months ago

GSK to Receive $370 Million in U.S. Patent Litigation Settlement

Aug 1, 2025, 12:01 PM EDT - 3 months ago

Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges

ABBV AMGN AZN BMY GILD JNJ LLY

Jul 31, 2025, 3:35 PM EDT - 3 months ago

Pharma Companies Should Immediately Cut Down Drug Prices, Trump Says

ABBV AMGN AZN BMY GILD JNJ LLY

Jul 31, 2025, 3:00 PM EDT - 3 months ago

Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days.

ABBV AMGN AZN BMY GILD JNJ LLY

Jul 31, 2025, 2:28 PM EDT - 3 months ago

Trump pressures 17 pharma CEOs to cut US drug prices

ABBV AMGN AZN BMY GILD JNJ LLY

Jul 31, 2025, 2:19 PM EDT - 3 months ago

Trump posts letters to 17 pharmaceutical companies about drug prices

ABBV GILD LLY PFE AMGN AZN BMY

Jul 31, 2025, 1:48 PM EDT - 3 months ago

Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days

ABBV AMGN AZN BMY GILD JNJ LLY

Jul 30, 2025, 5:56 PM EDT - 3 months ago

GSK plc (GSK) Q2 2025 Earnings Call Transcript

Jul 30, 2025, 11:32 AM EDT - 3 months ago

GSK CEO: Innovation is the secret to bringing down cost of overall healthcare

Jul 30, 2025, 5:26 AM EDT - 3 months ago

GSK in talks with Trump administration on U.S. drug pricing, CEO says

Jul 30, 2025, 2:12 AM EDT - 3 months ago

GSK expects annual sales and profit at top end of forecast range

Jul 28, 2025, 12:41 PM EDT - 3 months ago

GSK: I Foresee Only Very Modest Upside Here Even If Blenrep Gets FDA Approval

Jul 27, 2025, 10:35 PM EDT - 3 months ago

Jiangsu Hengrui grants GSK global rights to drug portfolio in $500 million deal

Jul 27, 2025, 9:53 PM EDT - 3 months ago

Hengrui Pharma and GSK enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology

Jul 24, 2025, 12:27 PM EDT - 3 months ago

GSK's blood cancer drug gets EU approval for multiple myeloma

Financial_Doc Oct. 24 at 2:59 PM

$GSK what's going on here after FDA approval?

1 · Reply

OpenOutcrier Oct. 24 at 12:23 PM

$GSK (-5.0% pre) GSK shares fall as narrow approval of blood cancer drug limits US relaunch https://ooc.bz/l/81736

0 · Reply

Paulzk Oct. 24 at 10:21 AM

$GSK Not the final word on GSK multiple myeloma , another in phase 2 , phase 1 and 2 newly registered. Many drugs in the pipeline. buy the dip https://www.gsk.com/en-gb/innovation/pipeline/

0 · Reply

AlertsAndNews Oct. 24 at 2:36 AM

0 · Reply

drewfin87 Oct. 23 at 9:55 PM

$GSK what’s up with the price action at the end of today? That bounce off of news was sold off so fast that I thought it was a glitch…

2 · Reply

SuperGreenToday Oct. 23 at 9:49 PM

0 · Reply

Whytheykeepmutingme Oct. 23 at 9:15 PM

$GSK fda approval is bad news?

0 · Reply

OptionRunners Oct. 23 at 8:01 PM

0 · Reply

CrispDry Oct. 23 at 8:01 PM

$GSK the heck?

0 · Reply

levans80 Oct. 23 at 7:59 PM

$GSK Closed out some call options right before the bell. Nice profit on that spike into close.

0 · Reply

OptionRunners Oct. 23 at 7:58 PM

$GSK spiking into the close

0 · Reply

Wolly99 Oct. 22 at 7:50 PM

$ALT I still find it crazy interesting that $GSK is building out their clinical imaging in hepatology/renal/etc…but the verbiage suggests current liver projects. The fact that they prefer experience with “clinical radiology” and “quantitative analysis” would refer to only a could have very MASH-relevant MRI biomarkers: MRE, PDFF and cT1. Quantitative MRI isn’t really a thing outside of these in the clinical setting. Recall that GSK has the only “unpaired” FGF21 asset - meaning the other FGFs (efrux and pegoza) hav been bought and are now linked to GLP-1s (sema and survodutide) as part of a full obesity/MASLD/MASH pipeline. GSK still needs the GLP-1 part on the front end. I think they’d be wise to partner/bo pemvi, as it’s the only GLP-1 that is p3 ready in the US, and with Glucagon, it makes so much sense.

1 · Reply

look2theblue Oct. 22 at 6:31 PM

$ITRM Backed by $PFE science. $35M marketcap in a $10B marketspace, 14+ years of patent life. $PFE isn't going to concede the UTI market to $GSK this will get resolved.

0 · Reply

look2theblue Oct. 22 at 2:59 PM

$ITRM the single biggest check in Iterum’s favor for an acquisition by $PFE is that $PFE is unlikely to just roll over and concede the entire multibillion dollar UTI market to $GSK and Blujepa for the next 15 years.

1 · Reply

BTC321 Oct. 22 at 11:55 AM

$NVAX 🚨 $NVAX just dumped a site for $60 M cash and chopped $230 M in future costs. CEO calls it “leaner and more agile.” That’s not cost cutting — that’s house-cleaning before company shows up with a checkbook. 💼 Shah Capital’s been whispering “strategic options” for months. Add the new peer-reviewed mucosal immunity data (IgA antibodies — the real deal) and you’ve got a biotech that suddenly looks 🔥 to Big Pharma. $CSL? $GSK? Sanofi?$SNY $MRK or Serum Institute? Someone’s running the numbers. 🧮 The street’s asleep. Shorts are drunk. Watch what happens when the phone rings. ☎️ #NVAX #Novavax #M&A #TakeoverWatch #Biotech #ShortSqueeze #ScienceWins next $BYND

0 · Reply

sergiustrading Oct. 22 at 9:33 AM

$GSK

0 · Reply

Quantumup Oct. 21 at 8:31 PM

Clear Street🏁 $SGMT Buy/$29 $MDGL Boston Pharma - $GSK $IVA VKTX $ALGS Clear Street said: We initiate coverage of SGMT with a Buy, reflecting the highly attractive profile of once-daily oral denifanstat—an asset leveraging robust multi-modal biology akin to FGF21 analogs, which have recently driven prominent M&A activity within the MASH space. Denifanstat's exceptional P2b F2-F3 data, outstanding P3 acne results, and forward-looking development plans for F4C in combination with Madrigal Pharmaceuticals' (MDGL: Nasdaq, Buy, $431 PT) REZDIFFRA, all underpinned by a solid $135.5M cash position (runway into 2027), and anticipated readouts from ongoing P1 trials, together position SGMT as a compelling growth story. Even under conservative valuation metrics, comparable to Boston Pharma's recent $1.2B upfront acquisition, our $29 PT implies substantial upside relative to SGMT's current $188M EV.

0 · Reply

BiotechBonesaw Oct. 21 at 1:31 PM

$ALT I asked ChatGPT for the most likely acquirers. Interestingly they had $NVO as #1, followed by Roche, $GILD , $PFE , and $GSK . Any of those make sense to me - we’ll see what happens after the 48 week data is released soon 🕰️

0 · Reply

aletz Oct. 21 at 1:18 PM

$ALGS all the antigens have not rebounded significantly and stayed almost the same level it left after stopping taking pevy, absolutely ground breaking compared to the current standard of care. Big pharmas will be watching very closely, but ALGS has no interest of letting pevy go now. $GSK $RHHBY $GILD

1 · Reply

GTDaytona Oct. 21 at 12:03 PM

$SPRO $GSK

0 · Reply

GTDaytona Oct. 21 at 12:02 PM

$SPRO $GSK

0 · Reply

sweet_Journey Oct. 21 at 9:55 AM

$SPRO $GSK 🔥

0 · Reply

Market Cap	92.57B
Revenue (ttm)	40.10B
Net Income (ttm)	3.29B
EPS (ttm)	N/A
PE Ratio	10.49
Forward PE	10.10
Profit Margin	8.21%
Debt to Equity Ratio	1.21

Volume	9,860,100
Avg Vol	4,784,672
Day's Range	N/A - N/A
Shares Out	2.03B
Stochastic %K	10%
Beta	0.53
Analysts	Sell
Price Target	$40.39